In a clinical trial by Fu et al., TRPV6 was targeted in individuals with advanced epithelial-origin tumours, revealing that SOR-C13, an inhibitor of TRPV6, exhibit anti-cancer effects without any typical chemotherapy-related complications[138]. Here, TRPV6 is linked to neoplasm.